Medication info
BIDAGLIMET Tablet 50/850 mg (Vildagliptin, Metformin)

BIDAGLIMET Tablet 50/850 mg (Vildagliptin, Metformin)

Prescription medicationTabletOral
Ingredient · strength
Vildagliptin Hydrochloride›56mg / 1 tabletMetformin Hydrochloride›850mg / 1 tablet
Manufacturer / importer
Hanmi Pharmaceutical Co., Ltd.
Appearance
Yellow oval film-coated tablets
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 202105311 · Approved 2021.07.13 · Insurance code 643508430

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
In the treatment of patients with type 2 diabetes mellitus, the dose of this medicine should be individualized based on efficacy and tolerability, without exceeding vildagliptin 100mg and metformin 2000mg. A daily dose of vildagliptin of 100mg or more is not recommended. This medicine should generally be taken with food or immediately after a meal to reduce gastrointestinal adverse reactions caused by metformin. 1. Patients who have not previously received drug treatment for diabetes and whose blood glucose cannot be adequately controlled with monotherapy: The initial dose of this medicine is 1 tablet of 50/500mg once daily. The dose may be gradually increased to 1 tablet of 50/1000mg twice daily. 2. Patients whose blood glucose is not adequately controlled with metformin monotherapy: The initial dose of this medicine should provide vildagliptin 100mg daily and the patient's current dose of metformin. The initial dose is determined according to the patient's current treatment regimen. Take 1 tablet of this medicine, 50mg/850mg or 50mg/1000mg, twice daily, in the morning and evening. 3. Patients switching from combination therapy with vildagliptin and metformin: Patients switching from combination therapy with vildagliptin and metformin to this medicine may start at their previous doses of vildagliptin and metformin. 4. Use in combination with a sulfonylurea or insulin: Administer vildagliptin 50mg twice daily (total daily dose 100mg) and metformin at a dose similar to the patient's previous dose. - When this medicine is used in combination with a sulfonylurea, the sulfonylurea dose may need to be reduced to lower the risk of hypoglycemia. If you miss a dose of this medicine, take it with your next meal unless it is time to take the next dose. Do not take a double dose at one time to make up for the missed dose.

Ingredients

Manufacturer
Hanmi Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

View approved original text

This medication combines vildagliptin and metformin, which are effective for blood sugar control, to assist patients with type 2 diabetes in managing their blood sugar levels. Better results can be expected when used in conjunction with dietary and exercise regimens. This medication stabilizes blood sugar and aids in diabetes management.

How to take

Adult dose

In the treatment of patients with type 2 diabetes mellitus, the dose of this medicine should be individualized based on efficacy and tolerability, without exceeding vildagliptin 100mg and metformin 2000mg. A daily dose of vildagliptin of 100mg or more is not recommended. This medicine should generally be taken with food or immediately after a meal to reduce gastrointestinal adverse reactions caused by metformin. 1. Patients who have not previously received drug treatment for diabetes and whose blood glucose cannot be adequately controlled with monotherapy: The initial dose of this medicine is 1 tablet of 50/500mg once daily. The dose may be gradually increased to 1 tablet of 50/1000mg twice daily. 2. Patients whose blood glucose is not adequately controlled with metformin monotherapy: The initial dose of this medicine should provide vildagliptin 100mg daily and the patient's current dose of metformin. The initial dose is determined according to the patient's current treatment regimen. Take 1 tablet of this medicine, 50mg/850mg or 50mg/1000mg, twice daily, in the morning and evening. 3. Patients switching from combination therapy with vildagliptin and metformin: Patients switching from combination therapy with vildagliptin and metformin to this medicine may start at their previous doses of vildagliptin and metformin. 4. Use in combination with a sulfonylurea or insulin: Administer vildagliptin 50mg twice daily (total daily dose 100mg) and metformin at a dose similar to the patient's previous dose. - When this medicine is used in combination with a sulfonylurea, the sulfonylurea dose may need to be reduced to lower the risk of hypoglycemia. If you miss a dose of this medicine, take it with your next meal unless it is time to take the next dose. Do not take a double dose at one time to make up for the missed dose.

Precautions

This medication can cause severe lactic acidosis or hypoglycemia, and should not be used, particularly in patients with moderate to severe renal impairment or those with heart failure. Discontinue this medication at least 48 hours before any examination that uses iodinated contrast agents, and resume only after confirming normal renal function post-examination. Patients with allergies to this medication, those with type 1 diabetes, acute metabolic acidosis patients, or women who are pregnant or breastfeeding should not use this medication. Irregular meals, intense physical activity, or taking other medications may increase the risk of hypoglycemia and lactic acidosis, so caution is required. During treatment, liver function and renal function should be monitored regularly, and if abnormalities are found, consult a physician immediately. If symptoms of acute pancreatitis occur, stop taking the medication immediately and seek medical advice, and be cautious in cases with a history of acute pancreatitis. Excessive alcohol consumption increases the risk of lactic acidosis, so avoid alcohol while taking this medication. Elderly patients are at higher risk of renal function decline, thus dosage adjustments and regular renal function tests are necessary. If symptoms of hypoglycemia occur, consume sugar immediately, and if severe, inform healthcare personnel. Patients scheduled for surgery should stop taking this medication 48 hours prior to surgery and only resume once oral intake has recovered and renal function is confirmed normal post-surgery. This medication is not recommended for children and adolescents. In case of overdose, seek appropriate medical attention immediately; this medication can be removed through hemodialysis, so dialysis treatment may be necessary if required. If unusual symptoms such as blisters or ulcerations on the skin occur, inform the physician immediately and seek medical care. During treatment, regularly check blood sugar and hemoglobin A1c levels to verify treatment effectiveness and safety.

Side effects

Severe lactic acidosis, hypoglycemia, hepatitis, liver function abnormalities, elevated transaminase levels, angioedema, tremors, headaches, dizziness, fatigue, nausea, hypoglycemia, gastroesophageal reflux, diarrhea, bloating, chills, blood sugar reduction, asthenia, hyperhidrosis, constipation, arthralgia, upper respiratory infection, nasopharyngitis, peripheral edema, nausea, vomiting, diarrhea, abdominal pain, loss of appetite, dysgeusia, erythema, pruritus, urticaria, pancreatitis, urticaria, blisters, exfoliative skin lesions, severe and disability-associated arthralgia, cutaneous vasculitis, cholecystitis, dyspepsia, abdominal discomfort, gastrointestinal abnormalities, increased serum amylase, increased lipase, vesicular pemphigoid, myalgia, paresthesia, fever, edema, swelling of hands and feet, elevated creatine phosphokinase, elevated AST, increased C-reactive protein, elevated myoglobin levels

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture; therefore, it must be stored in a tightly closed container. Maintain a storage temperature between 1 to 30 degrees Celsius at room temperature, avoiding humid places.

Appearance and packaging

Appearance

Yellow oval film-coated tablets

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.